Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Joan Chang 1 , Morghan C. Lucas 2 , Lidia E. Leonte 1 , Marc Garcia-Montolio 1 , Lukram Babloo Singh 1 , Alison D. Findlay 3 , Mandar Deodhar 3 , Jonathan S. Foot 3 , Wolfgang Jarolimek 3 , Paul Timpson 2 , Janine T. Erler 1 , Thomas R. Cox 1, 2 1 Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark 2 The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia 3 Pharmaxis Pharmaceutical Ltd., Frenchs Forest, Australia Correspondence to: Thomas R. Cox, email: t.cox@garvan.org.au Janine T. Erler, email: janine.erler@bric.ku.dk Keywords: lysyl oxidase-like 2, lysyl oxidase, breast cancer, metastasis Received: August 26, 2016 Accepted: January 17, 2017 Published: February 10, 2017 ABSTRACT Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors. Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer. We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer. Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis. Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver. Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
Self-citationRetractedCox, T. R., & Erler, J. T. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.004077 · Cited by 1,569
Self-citationErez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Olumi, A., Grossfeld, G., Hayward, S., Carroll, P., Cunha, G., Hein, P., & Tlsty, T. (2000) · Breast Cancer Research · doi:10.1186/bcr138 · Cited by 1,463
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
Self-citationBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis
Cox, T. R., Bird, D., Baker, A.-M., Barker, H. E., Ho, M. W.-Y., Lang, G., & Erler, J. T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2233 · Cited by 571 · cited 3×
“The primary LOX antibody (synthesized by OpenBiosystems) targets a conserved peptide sequence from the active site of human and mouse LOX proteins and has been shown not to bind other LOX family members [25, 26, 34].”
BackgroundMethodSelf-citationCancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., Wang, J., Li, B., Yin, W., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-3942-9 · Cited by 138 · cited 1×
“However recent reports would imply they are inexplicably intertwined in other solid tumours [31, 32].”
BackgroundTumor-Secreted LOXL2 Activates Fibroblasts through FAK Signaling
Barker, H. E., Bird, D., Lang, G., & Erler, J. T. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0033-t · Cited by 119 · cited 3×
“We have previously shown that high tumor LOXL2 levels are correlated with an increase in cancer associated fibroblasts (CAFs) within tumors [20].”
BackgroundMethodSelf-citation
Cited by
The Extracellular Matrix Modulates the Metastatic Journey
Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 537
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
Jiang, Y., Zhang, H., Wang, J., Liu, Y., Luo, T., & Hua, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01252-0 · Cited by 491
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
Lysyl oxidases: from enzyme activity to extracellular matrix cross-links
Vallet, S. D., & Ricard-Blum, S. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180050 · Cited by 335
Yamauchi, M., Barker, T. H., Gibbons, D. L., & Kurie, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93554 · Cited by 270
Tissue Force Programs Cell Fate and Tumor Aggression
Northey, J. J., Przybyla, L., & Weaver, V. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0733 · Cited by 237
“This includes pirfenidone treatment, which reduces TGFβ activity (85), LOXL2 inhibitors to prevent collagen cross-linking (86, 87), hedgehog inhibitors to reduce collagen deposition (88, 89), and most recently vitamin D receptor manipulations to convert pancreatic stellate cells back into a quiescent state (90).”
BackgroundExtracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Nguyen, E. V., Pereira, B. A., Lawrence, M. G., Ma, X., Rebello, R. J., Chan, H., Niranjan, B., Wu, Y., Ellem, S., Guan, X., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001496 · Cited by 107
“9B) whereas PXS-S2A treatment impaired CAF migration at both 10 nM and 100 nM concentrations (Figs.”
BackgroundMethodInfluentialSelf-citationLysyl oxidase inhibitors in colorectal cancer progression
Liu, M., Wang, J., & Liu, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2024.102233 · Cited by 13
Metadata
- Authors
- Chang, J., Lucas, M. C., Leonte, L. E., Garcia-Montolio, M., Singh, L. B., Findlay, A. D., Deodhar, M., Foot, J. S., Jarolimek, W., Timpson, P., Erler, J. T., & Cox, T. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-10
- Volume
- 8
- Issue
- 16
- Pages
- 26066-26078
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2588314637
- Cited by
- 112
- References
- 9
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.